Oppenheimer Maintains Outperform on IDEAYA Biosciences, Lowers Price Target to $53
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Matthew Biegler maintains an Outperform rating on IDEAYA Biosciences (NASDAQ:IDYA) but lowers the price target from $60 to $53.
August 07, 2024 | 11:51 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Oppenheimer maintains an Outperform rating on IDEAYA Biosciences but lowers the price target from $60 to $53.
The Outperform rating suggests continued confidence in the company's performance, but the lowered price target indicates a more cautious outlook. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100